UPDATE: Angelini Pharma has just announced an exclusive option agreement with Sovargen to license the global development and commercialization rights for SVG105, a promising pre-clinical compound aimed at treating brain health diseases. This significant agreement was confirmed today, September 22, 2025, and underscores the urgent need for innovative treatments in the realm of neurological disorders.
The agreement allows Angelini Pharma to lead collaborative pre-clinical development efforts for SVG105, with plans to advance the compound into clinical trials outside of the Republic of Korea, China, Hong Kong, Macau, and Taiwan. This potentially revolutionary compound utilizes cutting-edge anti-sense oligonucleotide technology to target mTOR pathways, which are crucial for addressing various brain health disorders, including drug-resistant childhood epilepsy.
Under the terms of the agreement, Sovargen will receive an upfront payment and could earn up to approximately $550 million in milestone-dependent payments and royalties based on sales after approval. “This partnership with Sovargen further solidifies Angelini Pharma’s leading role in the field of brain health,” stated Jacopo Andreose, CEO of Angelini Pharma. The need for effective treatments is critical; many people with epilepsy remain uncontrolled despite current therapies.
This announcement follows a series of strategic partnerships by Angelini Pharma aimed at expanding its portfolio in brain health. Recently, the company collaborated with GRIN Therapeutics for rights to radiprodil and secured an asset purchase agreement for OmniAb’s RO’599, both aimed at addressing significant gaps in treatment for neurological disorders.
The implications of this new agreement are profound as brain health conditions affect millions globally, with an estimated 50 million people living with epilepsy alone. In Europe, around six million individuals are affected, highlighting the urgent need for advancements in treatment options.
Cheolwon Park, CEO of Sovargen, expressed enthusiasm about the collaboration, stating, “Our research so far demonstrates great potential for SVG105 to transform the treatment landscape in brain health.” This sentiment echoes the growing urgency in the pharmaceutical industry to address the substantial burden of neurological disorders, which contribute significantly to global health challenges.
As the partnership progresses, attention will be focused on the development milestones for SVG105, with many hoping it will lead to new, effective solutions for those battling brain health conditions worldwide. This agreement marks a pivotal moment not only for Angelini Pharma and Sovargen but also for millions of patients in desperate need of innovative treatments.
Stay tuned for more updates on this developing story as the collaboration between Angelini Pharma and Sovargen unfolds, potentially signaling a new era in brain health treatment.
